Table 4

Case fatality in relation to predisposing factors and underlying diseases (univariate analysis)

Predisposing factor

All patients

Deceased

Survivors

p-value

RR (95% CI)

N = 149

N = 19

N = 130

n (%)

n (%)

n (%)


Obesitya

27 (23.7)

7 (70.0)

20 (19.2)

0.002

9.8 (2.3–41.3)

Current smoker or ex-smokerb

66 (48.5)

13 (92.9)

53 (43.4)

<0.001

16.9 (2.1–133.5)

Alcohol abuse

24 (16.1)

7 (36.8)

17 (13.1)

0.008

3.9 (1.3–11.2)

Type 1 diabetes

5 (3.4)

0 (0)

5 (3.8)

1

1.0 (0.9–1.0)

Type 2 diabetes

29 (19.5)

6 (31.6)

23 (17.7)

0.153

2.1 (0.7–6.2)

COPD

8 (5.4)

4 (21.1)

4 (3.1)

0.01

8.4 (1.9–37.1)

Haematological malignancy

11 (7.4)

0 (0)

11 (8.5)

0.36

0.9 (0.9–1.0)

Solid malignancy

15 (10.1)

3 (15.8)

12 (9.2)

0.41

1.8 (0.5–7.2)

Rheumatoid arthritis

7 (4.7)

3 (15.8)

4 (3.1)

0.045

5.9 (1.2–28.8)

Liver cirrhosis

4 (2.7)

1 (5.3)

3 (2.3)

0.42

2.4 (0.2–23.8)

Cardiac diseasec

44 (29.5)

6 (31.6)

38 (29.2)

0.834

1.1 (0.4–3.2)

McCabe II or IIId

24 (16.1)

3 (15.8)

21 (16.2)

1

1.0 (0.3–3.6)

Corticosteroid treatmente

18 (12.1)

2 (10.5)

16 (12.3)

0.824

0.8 (0.2–4.0)

Chronic diseasef

117 (78.5)

18 (94.7)

99 (76.2)

0.065

5.6 (0.7–43.9)

Age over 60 years

78 (52.3)

11 (57.9)

67 (51.5)

0.604

1.3 (0.5–3.4)

Male sex

79 (53.0)

14 (73.7)

65 (50.0)

0.053

2.8 (1.0–8.2)

Nosocomial infection

30 (20.1)

1 (5.3)

29 (22.3)

0.084

0.2 (0.03–1.5)


a(BMI >30), data available from 114 patients

bData available from 136 patients

cCoronary artery disease, valvular disease or documented heart failure

dMcCabe class II or III: ultimately fatal or rapidly fatal disease

eCorticosteroids used in a dose of over 5 mg per day during one month prior to the episode of bacteraemia

fAt least one chronic disease

Huttunen et al. BMC Infectious Diseases 2007 7:13   doi:10.1186/1471-2334-7-13

Open Data